Cetera Investment Advisers Acquires 5,581 Shares of Lantheus Holdings, Inc. $LNTH

Cetera Investment Advisers grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 19.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,943 shares of the medical equipment provider’s stock after purchasing an additional 5,581 shares during the period. Cetera Investment Advisers’ holdings in Lantheus were worth $2,779,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Quarry LP grew its holdings in shares of Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 470 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in Lantheus by 20.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock worth $103,000 after acquiring an additional 212 shares in the last quarter. AlphaQuest LLC increased its position in shares of Lantheus by 252.5% during the first quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock worth $161,000 after acquiring an additional 1,184 shares during the period. Bayforest Capital Ltd bought a new stake in shares of Lantheus during the first quarter valued at approximately $180,000. Finally, Klein Pavlis & Peasley Financial Inc. purchased a new stake in shares of Lantheus in the first quarter valued at approximately $222,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Down 0.5%

NASDAQ LNTH opened at $58.75 on Friday. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The firm has a market cap of $3.90 billion, a PE ratio of 15.63 and a beta of 0.04. The company has a 50 day moving average price of $54.42 and a 200 day moving average price of $64.40. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The company had revenue of $92.51 million during the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on LNTH shares. B. Riley reduced their price objective on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, September 16th. Mizuho decreased their price objective on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. JMP Securities lowered their price objective on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. TD Cowen cut their target price on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. Finally, Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Lantheus has an average rating of “Hold” and an average target price of $74.17.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.